High-dose Radiotherapy or Androgen Deprivation Therapy (HEAT) as Treatment Intensification for Localized Prostate Cancer: An Individual Patient-data Network Meta-analysis from the MARCAP Consortium.
- Kishan, AU
- Wang, X
- Sun, Y
- Romero, T
- Michalski, JM
- Ma, TM
- Feng, FY
- Sandler, HM
- Bolla, M
- Maingon, P
- De Reijke, T
- Neven, A
- Steigler, A
- Denham, JW
- Joseph, D
- Nabid, A
- Carrier, N
- Souhami, L
- Sydes, MR
- Dearnaley, DP
- Syndikus, I
- Tree, AC
- Incrocci, L
- Heemsbergen, WD
- Pos, FJ
- Zapatero, A
- Efstathiou, JA
- Guerrero, A
- Alvarez, A
- San-Segundo, CG
- Maldonado, X
- Xiang, M
- Rettig, MB
- Reiter, RE
- Zaorsky, NG
- Ong, WL
- Dess, RT
- Steinberg, ML
- Nickols, NG
- Roy, S
- Garcia, JA
- Spratt, DE
- MARCAP Consortium,
DOIAbstract
BACKGROUND: The relative benefits of radiotherapy (RT) dose escalation and the addition of short-term or long-term androgen deprivation therapy (STADT or LTADT) in the treatment of prostate cancer are unknown. OBJECTIVE: To perform a network meta-analysis (NMA) of relevant randomized trials to compare the relative benefits of RT dose escalation ± STADT or LTADT. DESIGN, SETTING, AND PARTICIPANTS: An NMA of individual patient data from 13 multicenter randomized trials was carried out for a total of 11862 patients. Patients received one of the six permutations of low-dose RT (64 to <74 Gy) ± STADT or LTADT, high-dose RT (≥74 Gy), or high-dose RT ± STADT or LTADT. OUTCOME MEASUREMENTS AND STATISTICAL ANALYSES: Metastasis-free survival (MFS) wa...
Add to ORKG